Di Yi Cai Jing·2025-09-28 10:53Core Viewpoint - The development of high-end medical device industry in Shanghai aims to enhance global competitiveness, with specific targets set for 2027, including over 500 new domestic third-class medical device registrations and over 100 products approved in overseas markets [1] Group 1: Industry Overview - The medical device CDMO (Contract Development and Manufacturing Organization) sector is compared to "precision handicrafts," indicating a more specialized and fragmented market compared to the "heavy industry" nature of biopharmaceutical CDMOs [3][5] - The market size of China's medical device industry is projected to reach 1.2 trillion yuan (approximately 1.2 trillion CNY) by 2024, highlighting significant growth potential [3] Group 2: CDMO Development and Challenges - Despite the growth potential, the medical device CDMO sector faces challenges, including a lack of large-scale providers akin to WuXi AppTec in biopharmaceuticals, and a predominance of low-value consumables in the current CDMO offerings [1][3] - The complexity and non-standard nature of medical devices make it difficult to establish a mature CDMO ecosystem, as the industry requires significant investment and expertise across multiple disciplines [6][7] Group 3: Market Dynamics and Trends - Many medical device companies prefer to build their own production lines to maintain control over core technologies and supply chains, with outsourcing primarily driven by cost efficiency and access to specialized capabilities [5][10] - The trend towards self-built production systems is evident as companies progress to mass production stages, although initial stages may benefit from CDMO partnerships [5][10] Group 4: Future Outlook - The future of medical device CDMOs in China is expected to improve as companies focus on specialization and collaboration with academic and research institutions, enhancing the overall ecosystem [7][12] - The integration of CDMO platforms into global supply chains is crucial for the competitiveness of Chinese medical device companies, with some platforms already establishing international R&D and manufacturing centers [12][13]